– ZT002 was safe and well tolerated in both biweekly and monthly dosing arms in patients with overweight or obesity with a tolerability profile aligned with the GLP-1RA class – The open-label extension with ZT002 120 mg, once-monthly, showed 17.1% reduction in body weight at 30 weeks Beijing, China, 12 September 2024 – Beijing QL […]
– Abstract on data from a two-part phase 1c, multiple ascending dose study accepted for oral presentation – – New data highlighting the Company’s lead drug candidate ZT002 for obesity – Beijing, China, 3 September 2024 – Beijing QL Biopharmaceutical Co., Ltd. (“QL Biopharm”), a clinical stage biopharmaceutical company developing innovative biologic drugs for the […]
Newly appointed CFO with significant experience in medical technology and public / private financing Insulin Pump system Kaleido to expand commercial roll out in Europe February 1, Utrecht, The Netherlands ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest and most precise Insulin Pump systems for treating people with type 1 Diabetes, is pleased to […]
Winner of two Queen’s Awards for Enterprise in Innovation and International Trade Highest year-on-year sales growth in the company’s 25-year history Keele, UK, 14 December 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is celebrating its 25th anniversary […]
The grant will enable leading international researchers to complete a clinical trial comparing the two most common treatment methods for preventing leg amputation among people with critical limb ischaemia. Critical limb ischaemia is a serious and debilitating disease that affects about 22 million people globally, and these are often people with diabetes and/or chronic kidney […]
